KR100692227B1 - 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도 - Google Patents

마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도 Download PDF

Info

Publication number
KR100692227B1
KR100692227B1 KR1020007011196A KR20007011196A KR100692227B1 KR 100692227 B1 KR100692227 B1 KR 100692227B1 KR 1020007011196 A KR1020007011196 A KR 1020007011196A KR 20007011196 A KR20007011196 A KR 20007011196A KR 100692227 B1 KR100692227 B1 KR 100692227B1
Authority
KR
South Korea
Prior art keywords
polypeptide
seq
tuberculosis
amino acid
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007011196A
Other languages
English (en)
Korean (ko)
Other versions
KR20010071138A (ko
Inventor
스케이키예서에이더블유
앨더슨마크
캠포스-네토안토니오
Original Assignee
코릭사 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/056,556 external-priority patent/US6350456B1/en
Priority claimed from US09/223,040 external-priority patent/US6544522B1/en
Application filed by 코릭사 코포레이션 filed Critical 코릭사 코포레이션
Publication of KR20010071138A publication Critical patent/KR20010071138A/ko
Application granted granted Critical
Publication of KR100692227B1 publication Critical patent/KR100692227B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020007011196A 1998-04-07 1999-04-07 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도 Expired - Fee Related KR100692227B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/056,556 1998-04-07
US09/056,556 US6350456B1 (en) 1997-03-13 1998-04-07 Compositions and methods for the prevention and treatment of M. tuberculosis infection
US09/223,040 1998-12-30
US09/223,040 US6544522B1 (en) 1998-12-30 1998-12-30 Fusion proteins of mycobacterium tuberculosis antigens and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020067009456A Division KR100797876B1 (ko) 1998-04-07 1999-04-07 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도

Publications (2)

Publication Number Publication Date
KR20010071138A KR20010071138A (ko) 2001-07-28
KR100692227B1 true KR100692227B1 (ko) 2007-03-09

Family

ID=26735428

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020067009456A Expired - Fee Related KR100797876B1 (ko) 1998-04-07 1999-04-07 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
KR1020007011196A Expired - Fee Related KR100692227B1 (ko) 1998-04-07 1999-04-07 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020067009456A Expired - Fee Related KR100797876B1 (ko) 1998-04-07 1999-04-07 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도

Country Status (17)

Country Link
US (2) US7186412B1 (enExample)
EP (1) EP1068329A2 (enExample)
JP (2) JP4227302B2 (enExample)
KR (2) KR100797876B1 (enExample)
CN (2) CN1163602C (enExample)
AU (1) AU753995B2 (enExample)
BR (1) BR9909472A (enExample)
CA (1) CA2326598C (enExample)
CZ (1) CZ302870B6 (enExample)
HU (1) HU228354B1 (enExample)
IL (1) IL138809A0 (enExample)
NO (2) NO332500B1 (enExample)
NZ (1) NZ507378A (enExample)
PL (1) PL202844B1 (enExample)
SA (1) SA99200488B1 (enExample)
TR (1) TR200002938T2 (enExample)
WO (1) WO1999051748A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101378240B1 (ko) 2008-02-22 2014-03-28 포항공과대학교 산학협력단 결핵 예방용 조성물

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
DE69941545D1 (de) 1998-11-04 2009-11-26 Isis Innovation Tuberkulose diagnose test
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20030027774A1 (en) * 1999-03-18 2003-02-06 Ronald C. Hendrickson Tuberculosis antigens and methods of use therefor
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US7009042B1 (en) 1999-10-07 2006-03-07 Corixa Corporation Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins
PT1517913E (pt) * 1999-10-07 2007-05-31 Corixa Corp Sequência codificante de mycobacterium turberculosis para expressão de proteínas heterólogas.
CA2386841A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US6316205B1 (en) 2000-01-28 2001-11-13 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection
WO2001062893A2 (en) 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
GB0006692D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Epitopes
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU6867801A (en) * 2000-06-20 2002-01-02 Corixa Corp Fusion proteins of mycobacterium tuberculosis
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US6841159B2 (en) 2002-01-30 2005-01-11 The United States Of America As Represented By The Secretary Of The Navy Rapid lateral flow assay for determining exposure to Mycobacterium tuberculosis and other mycobacteria
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
AU2005289685B2 (en) 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
US8475735B2 (en) 2004-11-01 2013-07-02 Uma Mahesh Babu Disposable immunodiagnostic test system
KR101255870B1 (ko) 2004-11-16 2013-04-17 아에라스 글로벌 티비 백신 파운데이션 재조합 바이러스 벡터를 포함하는 다가 백신
CN100368437C (zh) * 2005-01-28 2008-02-13 中国农业科学院哈尔滨兽医研究所 一种诊断牛结核病的重组抗原蛋白及其制备方法
EP1877426B1 (en) 2005-04-29 2012-02-01 GlaxoSmithKline Biologicals SA Method for preventing or treating m tuberculosis infection
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN100999550B (zh) * 2006-01-10 2010-10-06 中国人民解放军第三○九医院 结核分枝杆菌融合蛋白及其应用
CN100415771C (zh) * 2006-06-06 2008-09-03 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
CN101311189B (zh) * 2006-06-06 2010-09-08 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
CN101298471B (zh) * 2006-06-06 2011-01-19 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
CN101311190B (zh) * 2006-06-06 2011-08-03 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
EP2402023A1 (en) * 2006-06-28 2012-01-04 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
WO2008043774A1 (en) 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
LT2137210T (lt) 2007-03-02 2016-12-27 Glaxosmithkline Biologicals Sa Naujas būdas ir kompozicijos
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
JP5378350B2 (ja) 2007-04-04 2013-12-25 インフェクティアス ディジーズ リサーチ インスティチュート 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ）ポリペプチドおよびその融合物を含む免疫原性組成物
CA2704178A1 (en) * 2007-10-13 2009-04-16 Cornell University Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis
NO2315597T3 (enExample) 2008-07-25 2018-01-20
SI2315773T1 (sl) * 2008-07-25 2016-12-30 Glaxosmithkline Biologicals S.A. Polipeptidi, polinukleotidi in sestavki za uporabo pri zdravljenju latentne tuberkuloze
EP2315834B1 (en) 2008-07-25 2018-06-13 GlaxoSmithKline Biologicals S.A. The tuberculosis rv2386c protein, compositions and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
DK2406288T3 (en) 2009-03-10 2017-03-27 Baylor Res Inst ANTIGEN PRESENTING CELL-TARGETED VACCINES
ES2584956T3 (es) 2009-03-10 2016-09-30 Baylor Research Institute Anticuerpos anti-CD40 y usos de los mismos
CN105837691B (zh) 2009-03-10 2021-06-29 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
US8932600B2 (en) 2010-01-27 2015-01-13 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
DK2544693T3 (en) 2010-03-09 2017-12-04 Biomedical Res Models Inc Hitherto UNKNOWN ACCESS TO VACCINATION THROUGH MILKHINDER AGAINST HERPES SIMPLEX VIRUS TYPE-2
KR20190022897A (ko) 2010-12-14 2019-03-06 글락소스미스클라인 바이오로지칼즈 에스.에이. 미코박테리움 항원성 조성물
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
CN102154324B (zh) * 2010-12-29 2012-11-28 兰州大学 结核分枝杆菌融合蛋白Mtb10.4-Hsp16.3的构建、表达和纯化方法及其应用
CA2831294A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012149307A2 (en) 2011-04-27 2012-11-01 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
CN102305855A (zh) * 2011-05-19 2012-01-04 中山大学 体外检测结核分枝杆菌感染的试剂和方法
US20150196627A1 (en) * 2011-10-24 2015-07-16 University Of Central Florida Research Foundation, Inc. Plastid-expressed mycobacterium tuberculosis vaccine antigens esat-6 and mtb72f fused to cholera toxin b subunit
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
MX347154B (es) 2012-02-24 2017-02-21 Centro De Investigación Científica Y De Educación Superior De Ensenada Baja California (Cicese) Prueba de diagnóstico para enfermedades infecciosas en ganado bovino.
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
CN102757971B (zh) * 2012-08-07 2013-09-11 中国人民解放军第三O九医院 一种结核分枝杆菌重组蛋白质及其制备方法
WO2014063704A2 (en) * 2012-10-23 2014-05-01 Statens Serum Institut M. tuberculosis vaccines
ES2847930T3 (es) 2013-01-07 2021-08-04 Mucosal Vaccine Tech Llc Vacunas terapéuticas para el tratamiento de las infecciones por el virus del herpes simple de tipo 2
US9789175B2 (en) 2013-03-15 2017-10-17 The Trustees Of The University Of Pennsylvania Synthetic immunogens for prophylaxis or treatment of tuberculosis
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
CA3014458A1 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
EP4112638A1 (en) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
WO2017210364A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
AU2018285694B2 (en) 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
AU2018330165B2 (en) 2017-09-08 2025-07-17 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
CN109825497A (zh) * 2019-01-25 2019-05-31 石河子大学 一种新型结核杆菌融合菌株的制备方法及其应用
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
AU2023336224A1 (en) 2022-09-09 2025-03-27 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN118652311B (zh) * 2024-07-17 2025-02-25 扬州大学 结核分枝杆菌复合体ⅶ型分泌系统效应蛋白cfp10保守功能性b细胞表位及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009428A2 (en) * 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2084698T5 (es) 1989-05-04 2005-03-01 Southern Research Institute Procedimiento de encapsulacion.
JPH07500961A (ja) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
ATE199647T1 (de) 1991-05-14 2001-03-15 Univ Connecticut Gerichtete abgabe von genen, die immunogene proteine kodieren
AU2160992A (en) 1991-06-05 1993-01-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
DE69230305T2 (de) * 1991-08-15 2000-07-20 F. Hoffmann-La Roche Ag, Basel Primerpaar zum Nachweis von Mycobacterium
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
WO1993020221A1 (en) 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
DK79893D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
DK79793D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut Diagnostic test
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69636075D1 (de) * 1995-09-01 2006-06-01 Corixa Corp Verbindungen und verfahren zur diagnose von tuberkulose
US6627198B2 (en) * 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009428A2 (en) * 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101378240B1 (ko) 2008-02-22 2014-03-28 포항공과대학교 산학협력단 결핵 예방용 조성물

Also Published As

Publication number Publication date
NZ507378A (en) 2002-12-20
KR20010071138A (ko) 2001-07-28
JP2002510494A (ja) 2002-04-09
WO1999051748A3 (en) 2000-02-03
WO1999051748A9 (en) 2000-08-10
NO20005050L (no) 2000-11-30
HU228354B1 (en) 2013-03-28
PL202844B1 (pl) 2009-07-31
WO1999051748A2 (en) 1999-10-14
CZ302870B6 (cs) 2011-12-28
CN1629185B (zh) 2011-11-02
EP1068329A2 (en) 2001-01-17
HUP0101521A3 (en) 2004-10-28
NO20120621L (no) 2000-11-30
SA99200488B1 (ar) 2006-08-12
AU3481799A (en) 1999-10-25
US7186412B1 (en) 2007-03-06
KR20060064698A (ko) 2006-06-13
JP2006273858A (ja) 2006-10-12
PL344142A1 (en) 2001-10-08
BR9909472A (pt) 2001-09-11
IL138809A0 (en) 2001-10-31
CN1304451A (zh) 2001-07-18
CA2326598C (en) 2014-06-10
TR200002938T2 (tr) 2001-02-21
CN1629185A (zh) 2005-06-22
NO332500B1 (no) 2012-10-01
CN1163602C (zh) 2004-08-25
KR100797876B1 (ko) 2008-01-24
US20060171965A1 (en) 2006-08-03
JP4227302B2 (ja) 2009-02-18
HUP0101521A2 (hu) 2001-08-28
JP4326008B2 (ja) 2009-09-02
US7261897B2 (en) 2007-08-28
AU753995B2 (en) 2002-10-31
CA2326598A1 (en) 1999-10-14
CZ20003652A3 (en) 2001-05-16
NO20005050D0 (no) 2000-10-06

Similar Documents

Publication Publication Date Title
KR100692227B1 (ko) 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
US7335369B2 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
JP4516616B2 (ja) Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ抗原の融合タンパク質およびその使用
JP4382160B2 (ja) 結核の免疫治療および診断のための化合物および方法
JP4162155B2 (ja) 結核の免疫治療および診断のための化合物およびそれらの使用方法
US8143386B2 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
JP2002503683A (ja) 結核の免疫療法および診断のための化合物および方法
US6465633B1 (en) Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
HK1163176A (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
ZA200005505B (en) Fusion proteins of mycobacterium tuberculosis and their uses.
MXPA00009803A (en) Fusion proteins of mycobacterium tuberculosis
HK1059282B (en) Compounds for immunotherapy and diagnosis of tuberculosis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20120228

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140303

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140303